Company / Free Cash Flow
Moleculin Biotech, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$23.9M
FY2025
5-year range
-$27.7M / -$18.1M
FY2021-FY2025
Trend
-0.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$28M to -$24M over the past 2 years.
Based on SEC 10-K filings.
-$24M in FY2025.
Improved from -$28M to -$24M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow decreased 0.7% year-over-year.
- Peak free cash flow was recorded in FY2016.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -3.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$23.9M | -0.7% |
| FY2024 | -$23.7M | +14.4% |
| FY2023 | -$27.7M | -46.1% |
| FY2022 | -$19.0M | -4.5% |
| FY2021 | -$18.1M | -5.2% |
| FY2020 | -$17.3M | -36.7% |
| FY2019 | -$12.6M | -71.7% |
| FY2018 | -$7.4M | -94.2% |
| FY2017 | -$3.8M | -794.0% |
| FY2016 | -$423.5K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026